'Nature's Ozempic'? Berberine Won 6 of 6 Lipid Tests—With a Catch
Social media calls berberine "nature's Ozempic," but what does the science say? A 2025 overview pooled 54 systematic reviews covering 70 health outcomes. Berberine improved all 6 of 6 cholesterol outcomes and about 93% of type 2 diabetes outcomes. Obesity was its weakest area, and 45 of the 54 reviews were rated very low quality. Here is what the evidence supports, how berberine is commonly dosed, and who should steer clear.
Akkermansia Missed Its Main Goal—Except in People Who Lacked It
A pasteurized gut bacterium often pitched as a "natural GLP-1 booster" just faced a 142-person, double-blind trial, and it missed its primary insulin-sensitivity endpoint. But exploratory analyses showed a post-glucose GLP-1 rise, and people with low baseline Akkermansia saw better insulin sensitivity and less trunk fat. Those subgroup results are hypothesis-generating, sit close to the significance threshold, and come from a study with heavy industry involvement. Here is what the data show, what they don't, and who might care.